Branded (FDA-approved) vs. Compounded Semaglutide
Summary
Branded semaglutide (Ozempic, Wegovy, Rybelsus) is FDA-approved and reviewed for safety, effectiveness, and quality. Compounded semaglutide is prepared by pharmacies and is NOT FDA-approved or reviewed. This is the single most important distinction for anyone considering a telehealth GLP-1 program.
At a glance
| Dimension | Semaglutide | Compounded semaglutide |
|---|---|---|
| FDA approval | FDA-approved | Not FDA-approved (compounded) |
| Quality/potency review | Reviewed by FDA before marketing | Not reviewed by FDA for safety, effectiveness, or quality |
| Dosing formSelf-measurement raises overdose risk. | Pre-filled pen or standardized product | Often vials requiring patient self-measurement |
| Known FDA-reported issues | Established label warnings | Dosing errors, unapproved salt forms, contamination, counterfeits |
Semaglutide
- FDA approval
- FDA-approved
- Quality/potency review
- Reviewed by FDA before marketing
- Dosing form
- Pre-filled pen or standardized product
- Known FDA-reported issues
- Established label warnings
Compounded semaglutide
- FDA approval
- Not FDA-approved (compounded)
- Quality/potency review
- Not reviewed by FDA for safety, effectiveness, or quality
- Dosing form
- Often vials requiring patient self-measurement
- Known FDA-reported issues
- Dosing errors, unapproved salt forms, contamination, counterfeits
What they have in common
- Both may contain the semaglutide molecule and share its known GI and pancreatic risks.
- Both require a prescription and clinician oversight.
Material differences
- Only the branded product is FDA-approved and FDA-reviewed for quality.
- Compounded products are not verified for contents, potency, or purity.
- The FDA has documented adverse events and warned telehealth companies over compounded GLP-1 marketing.
Decision considerations
- Whether an FDA-approved product is accessible or affordable for you.
- If compounded is proposed, which licensed pharmacy prepares it and why.
- How the dose is measured and how to avoid self-measurement errors.
- Warning signs of contamination or overdose to watch for.
Sources
- 1.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 2.FDA Warns Telehealth Companies Against Illegal Marketing of Compounded GLP-1s — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 3.WEGOVY (semaglutide) injection — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
Last reviewed (yesterday)